{"organizations": [], "uuid": "c30c550d65a0446ec68d67deb5c0b19d2ecc5a12", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-onconova-therapeutics-announces-li/brief-onconova-therapeutics-announces-license-agreement-with-pint-pharma-to-commercialize-rigosertib-idUSFWN1QN0HL", "country": "US", "domain_rank": 408, "title": "BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.035, "site_type": "news", "published": "2018-03-05T21:11:00.000+02:00", "replies_count": 0, "uuid": "c30c550d65a0446ec68d67deb5c0b19d2ecc5a12"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-onconova-therapeutics-announces-li/brief-onconova-therapeutics-announces-license-agreement-with-pint-pharma-to-commercialize-rigosertib-idUSFWN1QN0HL", "ord_in_thread": 0, "title": "BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib", "locations": [], "entities": {"persons": [{"name": "onconova", "sentiment": "none"}, {"name": "rigosertib", "sentiment": "none"}], "locations": [{"name": "latin america", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "onconova therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Onconova Therapeutics Inc:\n* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA\n* ONCONOVA THERAPEUTICS INC - ONCONOVA ALSO ELIGIBLE TO RECEIVE UP TO $42.75 MILLION IN REGULATORY AND SALES MILESTONES\n* ONCONOVA THERAPEUTICS - IN EXCHANGE FOR RIGHTS, PINT WILL MAKE INVESTMENT TOTALING UP TO $2.5 MILLION BY PURCHASING SHARES AT A PREMIUM TO MARKET\n* ONCONOVA THERAPEUTICS INC - RIGOSERTIB TOP-LINE DATA EXPECTED IN 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T21:11:00.000+02:00", "crawled": "2018-03-06T22:36:40.001+02:00", "highlightTitle": ""}